Human Apolipoprotein E ELISA Kit | APOE elisa kit
Human Apolipoprotein E (APOE) ELISA Kit
Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays)
Three samples of known concentration were tested in forty separate assays to assess inter-assay precision.
CV (%) = SD/meanX100
Intra-Assay: CV
Inter-Assay: CV
NCBI and Uniprot Product Information
NCBI Description
The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mutations in this gene result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq, Jun 2016]
Uniprot Description
APOE: Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues. Defects in APOE are a cause of hyperlipoproteinemia type 3 (HLPP3); also known as familial dysbetalipoproteinemia. Individuals with HLPP3 are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD. Genetic variations in APOE are associated with Alzheimer disease type 2 (AD2). It is a late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known. Defects in APOE are a cause of sea-blue histiocyte disease (SBHD); also known as sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses. Defects in APOE are a cause of lipoprotein glomerulopathy (LPG). LPG is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians. Belongs to the apolipoprotein A1/A4/E family.
Protein type: Lipid-binding; Secreted; Secreted, signal peptide
Chromosomal Location of Human Ortholog: 19q13.32
Cellular Component: blood microparticle; cell soma; chylomicron; cytoplasm; dendrite; discoidal high-density lipoprotein particle; early endosome; endocytic vesicle lumen; endoplasmic reticulum; endoplasmic reticulum lumen; extracellular exosome; extracellular matrix; extracellular region; extracellular space; Golgi apparatus; high-density lipoprotein particle; intermediate-density lipoprotein particle; low-density lipoprotein particle; membrane; nucleus; plasma membrane; very-low-density lipoprotein particle
Molecular Function: amyloid-beta binding; antioxidant activity; cholesterol binding; cholesterol transporter activity; heparin binding; identical protein binding; lipid binding; lipid transporter activity; lipoprotein particle binding; low-density lipoprotein receptor binding; metal chelating activity; phospholipid binding; protein binding; protein dimerization activity; protein homodimerization activity; structural molecule activity; tau protein binding; very-low-density lipoprotein particle receptor binding
Biological Process: amyloid precursor protein metabolic process; artery morphogenesis; cellular calcium ion homeostasis; cellular oxidant detoxification; cellular protein metabolic process; cGMP-mediated signaling; cholesterol catabolic process; cholesterol efflux; cholesterol homeostasis; cholesterol metabolic process; chylomicron assembly; chylomicron remnant clearance; chylomicron remodeling; cytoskeleton organization; fatty acid homeostasis; G-protein coupled receptor signaling pathway; high-density lipoprotein particle assembly; high-density lipoprotein particle clearance; high-density lipoprotein particle remodeling; intracellular transport; lipid transport involved in lipid storage; lipoprotein biosynthetic process; lipoprotein catabolic process; long-chain fatty acid transport; long-term memory; low-density lipoprotein particle remodeling; maintenance of cellular localization; negative regulation of blood coagulation; negative regulation of blood vessel endothelial cell migration; negative regulation of canonical Wnt signaling pathway; negative regulation of cellular protein metabolic process; negative regulation of cholesterol biosynthetic process; negative regulation of endothelial cell proliferation; negative regulation of inflammatory response; negative regulation of long-term synaptic potentiation; negative regulation of MAP kinase activity; negative regulation of neuron apoptosis; negative regulation of neuron death; negative regulation of neuron projection development; negative regulation of platelet activation; negative regulation of presynaptic membrane organization; negative regulation of triglyceride metabolic process; neuron projection regeneration; nitric oxide mediated signal transduction; phospholipid efflux; positive regulation by host of viral process; positive regulation of amyloid fibril formation; positive regulation of cGMP biosynthetic process; positive regulation of cholesterol efflux; positive regulation of cholesterol esterification; positive regulation of endocytosis; positive regulation of lipid biosynthetic process; positive regulation of low-density lipoprotein particle receptor catabolic process; positive regulation of membrane protein ectodomain proteolysis; positive regulation of neuron projection development; positive regulation of nitric-oxide synthase activity; positive regulation of postsynaptic membrane organization; post-translational protein modification; protein import; receptor-mediated endocytosis; regulation of amyloid fibril formation; regulation of amyloid-beta clearance; regulation of axon extension; regulation of behavioral fear response; regulation of Cdc42 protein signal transduction; regulation of cellular response to very-low-density lipoprotein particle stimulus; regulation of cholesterol metabolic process; regulation of neuronal synaptic plasticity; regulation of protein homooligomerization; regulation of protein metabolic process; regulation of transcription from RNA polymerase II promoter; response to caloric restriction; response to dietary excess; response to reactive oxygen species; retinoid metabolic process; reverse cholesterol transport; synaptic transmission, cholinergic; triacylglycerol metabolic process; triglyceride catabolic process; triglyceride homeostasis; vasodilation; very-low-density lipoprotein particle remodeling; virus assembly
Disease: Alzheimer Disease 2; Alzheimer Disease 4; Hyperlipoproteinemia, Type Iii; Lipoprotein Glomerulopathy; Macular Degeneration, Age-related, 1; Sea-blue Histiocyte Disease
Research Articles on APOE
Similar Products
Product Notes
The Human APOE apoe (Catalog #AAA285462) is an ELISA Kit and is intended for research purposes only. The product is available for immediate purchase. The AAA285462 ELISA Kit recognizes Human APOE. It is sometimes possible for the material contained within the vial of "Apolipoprotein E, ELISA Kit" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
